Amarantus | GenomeWeb

Amarantus

The deals bring together Avant's ovarian cancer diagnostic, Amarantus' multiple sclerosis and Alzheimer's disease assays, and Theranostics' CLIA lab.

The deal brings together three firms that have struggled to ramp their test businesses in hopes that the combined outfit will be better positioned to succeed.

Avant and Amarantus, which agreed to merge in January, have now signed a deal to acquire Theranostics Health and its CLIA-certified laboratory.

When the merger is complete, Amarantus will own 80 million shares of Avant, representing about 45 percent of the combined company.

The theranostics company has repurchased all securities related to Discover Growth Fund's $5 million investment in April.

Amarantus will use the investment to develop and commercialize its neurology diagnostic products and drug candidates, and for other working capital expenses. 

Amarantus will use its LymPro Test to evaluate the pharmacodynamic effect of Anavex 2-73 and Anavex Plus on the expression of the biomarker CD69.

The deal opens the door for Amarantus to license as many as six patents to help diagnose patients at risk of developing Alzheimer's disease. 

DioGenix and its MSPrecise NGS test for multiple sclerosis will be merged into Amarantus as a foundational asset of a growing neuro-diagnostic business.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.